Cellmid 2017 Annual Report

DIRECTORS’

REPORT

CONTINUED

Meetings of Directors

Five meetings of the Directors were held during the ﬁnancial year. Attendances by each Director during the year were as follows:

Shares under option

Unissued ordinary shares of the Company under option at the date of this report are as follows:

36,366,503 shares were issued on the exercise of options during the ﬁnancial year ended 30 June 2017. No further shares have

been issued on exercise of options since 30 June 2017.

8,000,000 shares are vested and held in escrow at 30 June 2017 (12,000,000 held in escrow in 2016). 263,148,229 options lapsed

during the ﬁnancial year ended 30 June 2017 (600,000 in 2016).

Expiry date Exercise Price Number under option

Unlisted options 14 August 2017 $0.034 1,440,000

Unlisted options 1 August 2018 $0.040 4,000,000

Unlisted options 1 August 2018 $0.050 4,000,000

Unlisted options 1 August 2018 $0.060 10,000,000

Unlisted options 19 November 2018 $0.060 11,500,000

Unlisted options 19 November 2018 $0.031 500,000

Unlisted options 1 July 2020 $0.030 1,000,000

Unlisted options 31 October 2019 $0.030 2,000,000

34,440,000

Directors’ Meetings Audit Committee Nomination and

Remuneration Committee

Number Number Number Number Number Number

eligible to attended eligible to attended eligible to attended

attend attend attend

Dr David King 5 5 4 4 - -

Ms Maria Halasz 5 5 - 4 - -

Mr Bruce Gordon 5 5 4 4 - -

Dr Fintan Walton 5 5 4 4 - -

* by invitation